儿童特发性肺动脉高压预后及相关危险因素分析
该回顾性研究纳入119例儿童特发性肺动脉高压患者,平均诊断年龄5.9±4.2岁,中位随访22个月,死亡43例。5年生存率37.8%,基线NYHA心功能Ⅲ~Ⅳ级预后差,水肿是唯一独立危险因素,靶向药物可改善生存。
要点
- 儿童特发性肺动脉高压就诊时病情重,58.8%为NYHA Ⅲ~Ⅳ级,5年生存率仅37.8%。
- 基线NYHA分级、水肿、总胆红素及肌钙蛋白增高、肺动脉/主动脉内径比值大为预后危险因素。
- 应用波生坦、双药或三药联合靶向治疗为保护性因素,多因素分析仅水肿与生存下降独立相关。
核心结论
- 儿童特发性肺动脉高压患者就诊时病情重,心功能分级与预后相关。
- 基线NYHA分级Ⅲ~Ⅳ级患儿预后较差,靶向药物包括波生坦及双药或三药联合治疗可提高生存率。
研究设计与样本
- 回顾性研究纳入2007年6月至2017年5月北京安贞医院肺动脉高压中心年龄<18岁的特发性肺动脉高压患儿119例。
- 随访终点为死亡或肺移植,采用Kaplan-Meier法计算生存率,COX回归模型分析预后危险因素。
主要发现
- 入组患儿平均就诊年龄(5.9±4.2)岁,92例(77.5%)因活动量下降、活动后气促就诊。
- 70例(58.8%)基线NYHA分级Ⅲ~Ⅳ级,49例(41.2%)为Ⅰ~Ⅱ级。
- 中位随访22(0~108)个月,43例(36.1%)死亡,1例行双肺移植,死亡主因为右心衰竭、肺动脉高压危象、窒息及大咯血。
- 中位生存时间37.0个月,1、2、3、5年生存率分别为86.3%、72.2%、51.4%、37.8%。
- 多因素分析仅水肿与生存下降独立相关(HR=2.398,P=0.025)。
关键数值与推荐
- 超声心动图估测肺动脉收缩压平均(90±23)mmHg;50例右心导管测平均肺动脉压(66±19)mmHg。
- 右心导管测平均右房压(8.5±3.4)mmHg,肺小动脉阻力指数(17±9)wood·m²,心指数(3.4±1.3)L/m²。
- 100例(84.0%)接受靶向治疗,其中单药55例(46.2%)、双药40例(33.6%)、三药5例(4.2%)。
- COX回归显示NYHA分级、水肿、总胆红素增高、肌钙蛋白增高、肺动脉/主动脉内径比值为危险因素(HR=2.310、2.723、1.066、1.696、3.719,P=0.028、0.005、0.001、0.024、0.030)。
- 存在卵圆孔或房间隔缺损、应用波生坦、磷酸二酯酶抑制剂、双药和三药联合治疗为保护性因素(HR=0.563、0.559、0.603、0.682、0.044,P=0.169、0.076、0.115、0.258、0.220)。
临床怎么用
- 对儿童特发性肺动脉高压应关注基线NYHA分级,Ⅲ~Ⅳ级提示预后差。
- 水肿、总胆红素增高、肌钙蛋白增高及肺动脉/主动脉内径比值增大提示预后不良,需加强监测。
- 积极应用靶向药物包括波生坦及双药或三药联合治疗可能改善生存。
局限性
- 本研究为单中心回顾性研究,样本量有限。
- 仅50例患者进行了右心导管检查,血流动力学数据不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the prognosis and associated risk factors of pediatric idiopathic pulmonary arterial hypertension. Methods: A total of 119 patients under 18 years of age diagnosed as idiopathic pulmonary arterial hypertension in the Pulmonary Arterial Hypertension Center in Beijing Anzhen Hospital between June 2007 and May 2017 were enrolled in this retrospective study. The clinical informations and follow-up data were collected. The endpoints of follow-up were defined as death or undergoing lung transplantation. Kaplan-Meier survival curve was used to assess the survival,and the COX risk regression model was used to analyze the prognostic risk factors. Results: The mean age at diagnosis was (5.9±4.2) years. For 92 (77.5%) patients, the main reason for visit was decreased activity with shortness of breath after exercise. Seventy patients (58.8%) were in baseline NYHA functional class Ⅲ-Ⅳ and 49 patients (41.2%) were in NYHA functional class Ⅰ-Ⅱ. The mean systolic pulmonary arterial pressure estimated by echocardiography was (90±23) mmHg (1 mmHg=0.133 kPa) . Right heart catheterization was performed in 50 patients. Hemodynamic parameters revealed that the mean pulmonary artery pressure was (66±19) mmHg. Mean right atrium pressure was (8.5±3.4) mmHg. Mean pulmonary vascular resistance index was (17±9) wood·m(2) and the mean cardiac index was (3.4±1.3)L/m(2); 100 patients (84.0%) received targeted therapy in which 55 patients (46.2%) were on monotherapy,40 patients (33.6%) were on dual therapy and 5 patients (4.2%) were on triple therapy. The mean time of follow-up was 22.0 months (0-108 months). During follow-up, 43 patients (36.1%) died and 1 patient received double-lung transplantation. Main causes of death including right heart failure, pulmonary hypertension crisis, asphyxia and massive hemoptysis. The mean survival time from diagnosis was 37.0 months,1-,2-,3-and 5-year survival rates were 86.3%, 72.2%, 51.4%and 37.8% respectively. Survival analysis showed that patients in baseline NYHA functional class Ⅰ-Ⅱ had better prognosis. COX regression analysis showed that NYHA function class, edema, increased total bilirubin and troponin concentration and the pulmonary artery and aorta diameter ratio measured by echocardiogram are risk factors of pediatric IPAH (HR=2.310, 2.723, 1.066, 1.696, 3.719, P=0.028, 0.005, 0.001, 0.024, 0.030) . While the existence of aterial septal defect or patent foramen ovale, using bosentan and phosphodiesterase inhibitors(,) dual or triple therapy were protective factors (HR=0.563, 0.559, 0.603, 0.682, 0.044, P=0.169, 0.076, 0.115, 0.258, 0.220) . In multivariate analysis only edema associated with decreased survival (HR=2.398, P=0.025) . Conclusion: Childhood idiopathic pulmonary arterial hypertension patients are seriously ill at visit. Worse cardiac function classification at visit associate with high mortality. Target therapy including using bosentan, dual or triple therapy can improve survival. 目的: 对儿童特发性肺动脉高压的预后及其相关危险因素进行分析。 方法: 回顾性分析2007年6月至2017年5月就诊于北京安贞医院肺动脉高压中心的年龄<18周岁的特发性肺动脉高压患儿119例,对其进行临床资料收集和随访,随访的终点事件定义为死亡和行肺移植治疗。采用Kaplan-Meier法进行生存率计算以及生存曲线绘制,COX危险回归模型分析其预后相关危险因素。 结果: 入组患儿平均就诊年龄为(5.9±4.2)岁;92例(77.5%)患儿就诊的主要原因是活动量下降、活动后气促;70例(58.8%)患儿纽约心功能(NYHA)分级为Ⅲ~Ⅳ级,49例(41.2%)患儿NYHA分级为Ⅰ~Ⅱ级;超声心动图估测的肺动脉收缩压平均值为(90±23)mmHg(1 mmHg=0.133 kPa);50例患儿进行了右心导管检查,右心导管检查测平均肺动脉压(66±19)mmHg,平均右房压(8.5±3.4)mmHg,肺小动脉阻力指数(17±9)wood·m(2),心指数(3.4±1.3)L/m(2)。100例患儿(84.0%)给予了靶向药物治疗,55例(46.2%)为单药治疗,40例(33.6%)为双药联合治疗,5例(4.2%)为三药联合治疗。中位随访时间为22(0~108)个月,随访期间43例(36.1%)死亡,1例行双肺移植治疗,死亡的主要原因为右心衰竭、肺动脉高压危象、窒息以及大咯血。中位生存时间为37个月,1、2、3、5年生存率分别为86.3%、72.2%、51.4%和37.8%,生存分析显示基线NYHA分级Ⅰ~Ⅱ级患儿预后较好。COX回归分析显示NYHA分级、存在水肿、总胆红素增高、肌钙蛋白值增高,超声心动图测肺动脉/主动脉内径比值为影响预后的危险因素(HR=2.310、2.723、1.066、1.696、3.719,P=0.028、0.005、0.001、0.024、0.030)。存在卵圆孔或房间隔缺损,应用波生坦、磷酸二酯酶抑制剂,双药和三药联合治疗为预后保护性因素(HR=0.563、0.559、0.603、0.682、0.044,P=0.169、0.076、0.115、0.258、0.220)。多因素分析只有水肿是预后危险因素(HR=2.398,P=0.025)。 结论: 儿童特发性肺动脉高压患儿的就诊时间晚、病情重,就诊时的心功能分级和预后相关,心功能分级Ⅲ~Ⅳ级患儿预后差。靶向药物应用能改善部分患儿的预后,积极治疗包括应用波生坦,双药和三药联合治疗可提高生存率。.
引用
- Liu Q, Zhang C, Li QQ, et al. [Analysis of prognosis and associated risk factors in pediatric idiopathic pulmonary arterial hypertension]. Zhonghua Er Ke Za Zhi. 2018. PMID: 29342993. doi:10.3760/cma.j.issn.0578-1310.2018.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。